Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Cash from Investing Activities: 2013-2024

Historic Cash from Investing Activities for Seres Therapeutics (MCRB) over the last 12 years, with Dec 2024 value amounting to $142.3 million.

  • Seres Therapeutics' Cash from Investing Activities fell 100.01% to -$8,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$313,000, marking a year-over-year decrease of 100.22%. This contributed to the annual value of $142.3 million for FY2024, which is 1244.67% up from last year.
  • According to the latest figures from FY2024, Seres Therapeutics' Cash from Investing Activities is $142.3 million, which was up 1,244.67% from $10.6 million recorded in FY2023.
  • In the past 5 years, Seres Therapeutics' Cash from Investing Activities ranged from a high of $142.3 million in FY2024 and a low of -$158.9 million during FY2020.
  • In the last 3 years, Seres Therapeutics' Cash from Investing Activities had a median value of $82.4 million in 2022 and averaged $78.4 million.
  • As far as peak fluctuations go, Seres Therapeutics' Cash from Investing Activities crashed by 420.65% in 2020, and later spiked by 1,244.67% in 2024.
  • Seres Therapeutics' Cash from Investing Activities (Yearly) stood at -$158.9 million in 2020, then spiked by 140.33% to $64.1 million in 2021, then increased by 28.62% to $82.4 million in 2022, then crashed by 87.16% to $10.6 million in 2023, then spiked by 1,244.67% to $142.3 million in 2024.